BIOSECURE Act intelligence
Screen vendors, counterparties, and supplier networks against federal watchlists, then hand your team a report they can actually use.
Upload the file, run the screen, and see what needs attention before the conversation gets more expensive.
UPLOAD
matter packet
BIS
19,311 entries
OFAC
7,892 entries
DOD 1260H
1,261 entries
UFLPA
4,100+ entries
Every run captures the source lists, the match evidence, and when the screen happened.
When the screen finishes, the report shows flagged vendors, source lists, and the reason each name landed where it did.
PRE-AUDIT INTELLIGENCE REPORT
Vendor List · Q1 2026
Screened against BIS · OFAC · DoD 1260H · UFLPA
2
PROHIBITED
2
HIGH RISK
1
REVIEW
3
CLEARED
| Vendor Name | Country | Risk Tier | Match / Reason |
|---|---|---|---|
| Sangon Biotech Co., Ltd. | CN | PROHIBITED | BIS Entity List |
| BGI Genomics | CN | PROHIBITED | DoD 1260H · UFLPA |
| WuXi AppTec (HK) Ltd. | HK | HIGH RISK | Fuzzy match, DoD 1260H |
| Thermo Fisher Scientific | US | CLEARED | Cleared |
| Merck KGaA (Sigma-Aldrich) | DE | CLEARED | Cleared |
| Nanjing Vazyme Biotech | CN | REVIEW | Manual review |
| New England Biolabs | US | CLEARED | Cleared |
| Thermo Electron (Shanghai) | CN | HIGH RISK | Subsidiary risk |
8 vendors screened · Source lists current as of run date
This report is pre-audit analysis, not legal advice. If a finding needs a legal call, counsel makes it.
A clear explanation of what the product does, where it fits, and where it stops.
What we are
A fast first screen
Upload the list and get a report with matches, evidence, and the names that actually need a second look.
A report people can read quickly
Every screen shows the source list, the match logic, and the supporting detail in one place.
Fast enough for live diligence
Built for moments when a vendor, supplier, or counterparty needs to be cleared before the work moves forward.
Built around evidence
If something is flagged, you can see why it was flagged and what source triggered it.
What we are not
Legal advice
BioGate does not issue legal opinions. If a finding needs a legal determination, counsel makes that call.
A replacement for counsel
BioGate does not replace legal judgment. It helps your team get to the real issues faster.
A guarantee of BIOSECURE compliance
The OMB BCC list has not been published. BioGate screens against the closest available federal source lists and states that limitation in the report.
A dashboard product
The report is the deliverable. The product is built around screening and review, not daily dashboard management.
This is how BioGate stores data, refreshes source lists, and preserves a defensible record for each screening run.
TLS 1.3 in transit. AES-256 at rest. Your vendor list never travels in the clear.
Federal source lists are refreshed every 24 hours so new screenings use current data.
Customer data is access-controlled and kept separate at the database layer so each screening run stays scoped to your organization.
Access controls, audit logging, and change tracking are built into the workflow so sensitive screening work stays reviewable and contained.
Each screening run stores the timestamp, source-list snapshot, and supporting match evidence.
All data stored in US-only regions with database-level account isolation. Built for organizations with federal funding obligations.
Review the flagged names, decide what needs escalation, and move into the next conversation with something concrete in hand.
Uses federal source lists · Pre-audit analysis only
Ideas
The clinical timeline is no longer the monopoly concern of the biotech sector.
ReadThis Summer, the OMB will release a memo that will provide critical depth to the BIOSECURE Act. This memo is more important than the list of names expected in December.
Read